SIRT6 and melanoma: We identify SIRT6 as a regulator of resistance to the clinically relevant BRAF inhibitor (BRAFi), dabrafenib, or combination dabrafenib + trametinib (MEK inhibitor, MEKi) in BRAFV600E melanoma.